Episode
Liver Lineup: GLP-1 RAs and FGF21s for MASH, with Mary Rinella, MD
- Podcast
- HCPLive Podcasts
- Published
- Feb 3, 2026
- Duration seconds
- 1676
- Processing state
not_requested- Canonical source
- https://audioboom.com/posts/8856583
Actions
POST https://stenobird.com/v1/public/podcasts/hcplive-podcasts-19526/episodes/liver-lineup-glp-1-ras-and-fgf21s-for-mash-with-mary-rinella-md/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hcplive-podcasts-19526/liver-lineup-glp-1-ras-and-fgf21s-for-mash-with-mary-rinella-md.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of Liver Lineup: Updates and Unfiltered Insights , hosts Nancy Reau, MD, and Kimberly Brown, MD, sit down with Mary (Maru) Rinella, MD, a professor of medicine and director of Clinical Trials and the Metabolic and Fatty Liver Program at the University of Chicago, to discuss the rapidly evolving therapeutic landscape for metabolic dysfunction-associated steatohepatitis (MASH). Key Episode Timestamps: 0:00:00 – Introduction & guest bio 0:01:02 – Current therapy landscape & GLP‑1 overview 0:03:51 – Do GLP‑1s help non–weight losers? 0:05:21 – Combining GLP‑1s and resmetirom 0:07:23 – Pipeline GLP‑1 combinations & phase 2 data 0:09:26 – Advanced disease, sarcopenia & risk–benefit in cirrhosis 0:13:29 – Introduction to FGF‑21 agonists 0:14:04 – Symmetry (efruxifermin) trial & reading the data 0:17:51 – Endpoints, “lack of progression,” and FDA hurdles 0:19:41 – Need for non‑invasive surrogates 0:21:02 – FGF‑21 mechanism & other liver diseases 0:22:57 – Alcohol intake, GLP‑1s, FGF‑21 & MetALD 0:25:49 – 10‑year outlook & future toolbox 0:27:35 – Closing